ReviewClinics in liver disease2025
The Liver in Hematologic Malignancies: Lymphoma, Leukemia, and Myeloma.
Review in Clinics in liver disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in infections as risk factors for lymphoma: a review of the effects of viral, bacterial, and fungal infections in lymphoma.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Liver disease significantly impacts hematologic malignancies like lymphoma, leukemia, and multiple myeloma. Chronic hepatitis B and C increase risks, complicate treatment, and may lead to reactivation during chemotherapy. Bone marrow transplantation (BMT) is associated with the risk of hepatic complications. Antiviral therapy mitigates risks, improving survival. Screening and prophylactic treatment are essential for managing liver-related complications in these patients. Cirrhosis complicates the treatment of hematologic malignancies by altering drug metabolism, increasing toxicity, and heightening risks of complications. BMT further challenges liver function, with increased risk of complications like sinusoidal obstruction syndrome, requiring specialized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.